Minimal residual disease (MRD) in CLL is defined as the number of leukemic cells that can be detected in peripheral blood (PB) or bone marrow (BM) following treatment. Undetectable …

Dec 30, 2021 · Routine clinical, laboratory, and imaging methods do not currently detect occult residual tumor, which is referred as minimal (or, more precisely, measurable or detectable) …

Measurable residual disease (MRD) testing measures the amount of cancer cells that are present in blood or bone marrow at the time the sample was collected. This test can detect an …

Jun 24, 2021 · We recommend “MRD4” to identify cases with <10 −4 MRD (<1 CLL cell per 10 000 leukocytes, or <0.01%), “MRD5” to identify cases with <10 −5 MRD (<1 CLL cell per …

Mar 20, 2024 · One of the newest tools is testing for MRD, or measurable (AKA minimal) residual disease, which can detect very low levels of CLL in the blood or in the bone marrow, as …

• MRD can help identify which patients are at higher risk for relapse, allowing for earlier or additional treatments. MRD may also determine which patients may benefit from a bone …

Dec 8, 2023 · Detection of measurable residual disease (MRD) is a sensitive tool to identify disease burden following treatment with several therapeutic regimens in CLL (including CIT, …

Assessment of measurable residual disease (often referred to as “minimal residual disease”) has emerged as a highly sensitive indicator of disease burden during and at the end of treatment …

Feb 20, 2025 · Preliminary data from this study suggests that patients with CLL who are on venetoclax plus obinutuzumab and reach undetectable measurable residual disease (uMRD) …

Nov 5, 2020 · In CLL, undetectable MRD at the end of treatment in peripheral blood or bone marrow is associated with long-term survival (Thompson et al, Leukemia 2018). The …